Doctors order the PSEN1 genetic test when a patient's dementia symptoms worsen and the family history points toward early-onset Alzheimer's disease running through multiple generations. PSEN1 is a gene that, when it carries a harmful variant, causes a hereditary form of Alzheimer's that typically starts well before age 65.
The test is not a routine screen offered to every dementia patient — it is reserved for cases where the clinical picture and the family tree both point the same direction. (LabTests Online UK) As symptoms progress, clinicians use the result to confirm a diagnosis, explain the disease's likely course, and open a conversation about what the finding means for the patient's children. The test does not change treatment on its own, but it reframes the family's understanding of what is happening and why.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When Doctors Order This Test
- Why PSEN1 Matters So Much in Early-Onset Cases
- What a Positive Result Means for the Patient and Family
- What a Negative Result Does — and Doesn't — Rule Out
- Why Genetic Counseling Comes Before and After the Test
When Doctors Order This Test
Physicians request PSEN1 testing once a patient already has dementia symptoms and a strong family history of early-onset Alzheimer's disease spanning multiple generations — not as a general-population screen. (LabTests Online UK) This is called diagnostic testing, and it is distinct from predictive testing, which is offered separately to relatives who have no symptoms yet, after a specific PSEN1 variant has already been identified somewhere in their family.
(Clinical genetics review, PMC) The test is most useful in a specific group: patients under age 60 who have an affected parent or other close relative with the same pattern of early-onset disease. Doctors prioritize ordering the test for this group because the odds of finding a causative variant are highest here. (Clinical genetics review, PMC) Outside that profile — a patient with typical late-onset dementia and no strong family pattern — the test is far less likely to explain the disease, which is why doctors do not order it broadly.
Why PSEN1 Matters So Much in Early-Onset Cases
PSEN1 is the most frequently mutated gene behind early-onset familial Alzheimer's disease. Depending on the cohort studied, it accounts for roughly 20% to 70% of diagnosed early-onset familial cases. (Early-onset Dementia gene panel, PanelApp Australia) That makes PSEN1 the first and most important gene doctors check when the family history suggests a hereditary pattern.
But its importance is narrow in scope: PSEN1, along with two related genes, PSEN2 and APP, together explain only about 5% to 10% of all Alzheimer's disease cases overall. (Frontiers in Aging Neuroscience, 2022) In practice, this means PSEN1 testing is targeted squarely at the small early-onset familial subset of Alzheimer's disease. A patient with typical late-onset dementia and no family pattern is not part of the population this test was built for.
What a Positive Result Means for the Patient and Family
PSEN1-related disease is inherited in an autosomal dominant pattern, meaning a single altered copy of the gene is enough to cause disease. Each child of a confirmed carrier has a 50% chance of inheriting the same variant. Doctors use this figure directly when counseling families after a positive result.
(PathologyTestsExplained.org.au) A pathogenic PSEN1 variant is highly penetrant, meaning a carrier is very likely to eventually develop the disease. But penetrance is not the same as predictability: the age of onset, severity, and speed of progression still differ between individual carriers, even within the same family. (PathologyTestsExplained.org.au) This combination — near-certain eventual disease, but an uncertain timeline — is central to how doctors frame the result. A positive test confirms the diagnosis and clarifies the hereditary risk to children, but it cannot tell a family exactly when symptoms will appear in a given relative.
What a Negative Result Does — and Doesn't — Rule Out
A negative PSEN1 result does not rule out an inherited form of early-onset Alzheimer's disease. Standard genetic panels can miss variants in regulatory regions and deep intronic sequences, and some genes that cause inherited early-onset disease have not yet been identified.
(PathologyTestsExplained.org.au; Clinical genetics review, PMC) Clinical laboratories report that a broader familial early-onset Alzheimer's gene panel — testing PSEN1 alongside related genes — identifies a causative variant in roughly 60% to 80% of cases tested. Doctors share this figure with families before ordering testing, so expectations are set correctly from the start. (PathologyTestsExplained.org.au) A family that receives a negative result, in other words, is not necessarily free of inherited risk — they may carry a variant the test cannot yet detect.
Why Genetic Counseling Comes Before and After the Test
Doctors build genetic counseling into every stage of PSEN1 testing, not as a formality but because the emotional weight of the result is heavier than it looks on paper. In at least one study, people who received a negative PSEN1 result still reported psychological distress similar to those who tested positive, a year after getting their result. (Clinical genetics review, PMC) Counseling before testing helps a patient or relative understand what a positive, negative, or inconclusive result would actually mean for them and their children.
Counseling afterward helps process the result, regardless of which way it falls. Pediatric and prenatal PSEN1 testing is not recommended, because the age of symptom onset varies too much between carriers to make a result actionable at that stage of life. Testing is reserved for adults who can understand and act on what the result means.
